Testosterone treatment of hypogonadal men participating in competitive sports
- PMID: 18477208
- DOI: 10.1111/j.1439-0272.2008.00838.x
Testosterone treatment of hypogonadal men participating in competitive sports
Abstract
Testosterone has a steeply dose-dependent effect on muscle mass and strength irrespective of gonadal status. So, for reasons of fairness, people who engage in competitive sports should not administer exogenous testosterone raising their blood testosterone levels beyond the range of normal. There is a ban on exogenous androgens for men and women in sports, but an exception has been made for men with androgen deficiency due to pituitary or testicular disease. Men who receive testosterone administration for the indication hypogonadism have an interest in the use of testosterone preparations generating blood testosterone levels within the normal range of healthy, eugonadal men. On the grounds of a positive correlation between blood testosterone concentrations muscle and volume/strength, they are best served with a parenteral testosterone preparation, rather than transdermal testosterone, but they should not run the risk of being excluded from competition because of supraphysiological testosterone levels. The latter is a realistic risk with the traditional parenteral testosterone esters. The new parenteral testosterone undecanoate preparation offers much better perspectives. Its pharmacokinetics have been investigated in detail and there is a fair degree of predictability of resulting blood testosterone levels with use of this preparation.
Similar articles
-
A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.J Androl. 1998 Nov-Dec;19(6):761-8. J Androl. 1998. PMID: 9876028
-
Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.Andrologia. 2007 Oct;39(5):181-4. doi: 10.1111/j.1439-0272.2007.00785.x. Andrologia. 2007. PMID: 17714216 Clinical Trial.
-
Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.J Clin Endocrinol Metab. 1999 Oct;84(10):3469-78. doi: 10.1210/jcem.84.10.6078. J Clin Endocrinol Metab. 1999. PMID: 10522982 Clinical Trial.
-
More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate.Asian J Androl. 2007 May;9(3):291-7. doi: 10.1111/j.1745-7262.2007.00275.x. Asian J Androl. 2007. PMID: 17486268 Review.
-
Testosterone undecanoate in the treatment of male hypogonadism.Expert Opin Pharmacother. 2010 Aug;11(12):2095-106. doi: 10.1517/14656566.2010.505920. Expert Opin Pharmacother. 2010. PMID: 20642374 Review.
Cited by
-
Andrological aspects of physical exercise and sport medicine.Endocrine. 2012 Oct;42(2):278-84. doi: 10.1007/s12020-012-9655-6. Epub 2012 Mar 20. Endocrine. 2012. PMID: 22430368 Review.
-
Urinary and serum hormones profiles after testosterone enanthate administration in male hypogonadism: concerns on the detection of doping with testosterone in treated hypogonadal athletes.J Endocrinol Invest. 2009 May;32(5):445-53. doi: 10.1007/BF03346484. Epub 2009 Mar 24. J Endocrinol Invest. 2009. PMID: 19461217 Clinical Trial.
-
The significance of testosterone for fair participation of the female sex in competitive sports.Asian J Androl. 2011 Sep;13(5):653-4. doi: 10.1038/aja.2011.91. Epub 2011 Jul 4. Asian J Androl. 2011. PMID: 21725329 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources